References
- Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, Marteyn B, Farnoud NR, de Botton S, Bernard OA, et al. 2017. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 130(6):732–741. doi: https://doi.org/10.1182/blood-2017-04-779447
- Appelbaum FR, Rowe JM, Radich J, Dick JE. 2001. Acute myeloid leukemia. Hematology. 2001(1):62–86. doi: https://doi.org/10.1182/asheducation-2001.1.62
- Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, Quaranta D, Tonali PA, Barone C. 2011. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemother Pharmacol. 67(5):1179–1187. doi: https://doi.org/10.1007/s00280-010-1466-y
- Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Jeong Kim E, et al. 2017. NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Canc Netw. 15(7):883–893. doi: https://doi.org/10.6004/jnccn.2017.0117
- Bird A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev. 16(1):6–21. doi: https://doi.org/10.1101/gad.947102
- Dou LP, Jing Y, Wang QS, Mei JH, Yu L. 2013. Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21(3):662–666.
- Iris S, Matthew B, Veronika N, Chao W, Sara R, Nancy K, Fang-Yong L, Ehrenkranz RA, Rinder HM, Vineet B. 2013. Neutrophil CD64 with hematologic criteria for diagnosis of neonatal sepsis. Am J Perinatol. 31(1):021–030. doi: https://doi.org/10.1055/s-0033-1334453
- Momparler RL, Cote S, Momparler LF, Idaghdour Y. 2017. Inhibition of DNA and histone methylation by 5-aza-2'-deoxycytidine (decitabine) and 3-deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells. Front Oncol. 7:19. doi: https://doi.org/10.3389/fonc.2017.00019
- Nair CK, Kumar M, Odayoth SM. 2013. Pleural effusion during acute myeloid leukemia induction chemotherapy: a perplexing case. J Cancer Res Ther. 9(2):290–291. doi: https://doi.org/10.4103/0973-1482.113390
- Niitsu N, Hayashi Y, Sugita K, Honma Y. 2015. Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3. Br J Haematol. 112(2):315–326. doi: https://doi.org/10.1046/j.1365-2141.2001.02523.x
- Obara M, Ara T, Shima K, Yasumoto A, Nakata M, Ota S, Imai K, Hirano T, Kiyama Y, Ogasawara M. 2013. Aclarubicin, low-dose cytarabine combined with G-CSF (CAG) regimen for patients previously treated or ineligible for intensive chemotherapy with acute myeloid leukemia and myelodysplastic syndrom: a single center experience. Blood. 122:1241–1241. doi: https://doi.org/10.1182/blood.V122.21.1241.1241
- Qiao X, Yin F, Ji Y, Li Y, Yan P, Lai J. 2017. 5-Aza-2'-deoxycytidine in the medial prefrontal cortex regulates alcohol-related behavior and Ntf3-TrkC expression in rats. PLoS One. 12(6):e0179469. doi: https://doi.org/10.1371/journal.pone.0179469
- Ramos MP, Wijetunga NA, McLellan AS, Suzuki M, Greally JM. 2015. DNA demethylation by 5-aza-2'-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences. Epigenetics Chromatin. 8:11. doi: https://doi.org/10.1186/s13072-015-0004-x
- Rastogi N. 2018. Genetics of acute myeloid leukemia - a paradigm shift. Indian Pediatr. 55(6):465–468. doi: https://doi.org/10.1007/s13312-018-1334-0
- Robertson M, Schrey A, Shayter A, Moss CJ, Richards C. 2017. Genetic and epigenetic variation in Spartina alterniflora following the Deepwater Horizon oil spill. Evol Appl. 10(8):792–801. doi: https://doi.org/10.1111/eva.12482
- Sayad A, Hajifathali A, Hamidieh AA, Roshandel E, Taheri M. 2017. HOTAIR long noncoding RNA is not a biomarker for acute myeloid leukemia (AML) in Iranian patients. Asian Pac J Cancer Prev. 18(6):1581–1584.
- Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM. 2018. Effects of 5-aza-2'-deoxycytidine (decitabine) on gene expression. Drug Metab Rev. 50(2):193–207. doi: https://doi.org/10.1080/03602532.2018.1437446
- Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, et al. 2018. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 131(4):387–396. doi: https://doi.org/10.1182/blood-2017-06-789800
- Stich M, Ganss L, Puschhof J, Prigge ES, Reuschenbach M, Guiterrez A, Vinokurova S, Doeberitz MVK. 2017. 5-Aza-2′-deoxycytidine (DAC) treatment downregulates the HPV E6 and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer cells. Oncotarget. 8(32):52104–52117. doi: https://doi.org/10.18632/oncotarget.10631
- Tabayashi T, Takahashi Y, Kimura Y, Tomikawa T, Sagawa M, Anan T, Watanabe R, Tokuhira M, Mori S, Kizaki M. 2014. P1-21-1efficacy of low-dose cytarabine-based regimen(CAG)followed by azacitidine for elderly patients with MDS/AML. Ann Oncol. 25(suppl 5):v84–v84. doi: https://doi.org/10.1093/annonc/mdu436.42
- Wang J, Jiang B, Jiang Q, Lu J, Zhu HH, Yang SM, Zhao T, Wen L, Bao L, Huang XJ, et al. 2016. Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen. Zhonghua Xue Ye Xue Za Zhi. 37(3):194–200.
- Weinberg OK, Sohani AR, Bhargava P, Nardi V. 2017. Diagnostic work-up of acute myeloid leukemia. Am J Hematol. 92(3):317–321. doi: https://doi.org/10.1002/ajh.24648
- Xie MY, Yang Y, Liu P, Luo Y, Tang SB. 2019. 5-Aza-2'-deoxycytidine in the regulation of antioxidant enzymes in retinal endothelial cells and rat diabetic retina. Int J Ophthalmol. 12(1):1–7.
- Zheng C, Cai X, Wu S, Liu Z, Shi Y, Zhou W. 2014. Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia. Pak J Med Sci. 30(6):1270–1272.